{"id":496844,"date":"2020-07-17T17:00:01","date_gmt":"2020-07-17T17:00:01","guid":{"rendered":"https:\/\/www.abnewswire.com\/pressreleases\/?p=496844"},"modified":"2020-07-17T17:00:01","modified_gmt":"2020-07-17T17:00:01","slug":"cancer-cachexia-patient-population-treatment-algorithm-medical-practices-and-epidemiology-forecast-to-2030","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/cancer-cachexia-patient-population-treatment-algorithm-medical-practices-and-epidemiology-forecast-to-2030_496844.html","title":{"rendered":"Cancer Cachexia Patient Population, Treatment Algorithm, Medical Practices And Epidemiology Forecast To 2030"},"content":{"rendered":"
\"Cancer<\/a><\/p>\n
\n
Delveinsight Business Research<\/div>\n<\/div>\n<\/div>\n
DelveInsight’s ‘Cancer Cachexia Epidemiology Forecast to 2030’ report delivers an in-depth understanding of the disease, historical and forecasted Cancer Cachexia epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.<\/p>\n<\/div>\n

Cachexia is a complex metabolic multi\u2010organ syndrome characterized by at least 5% of weight loss, muscle and adipose tissue wasting and inflammation, as it taps into other sources of energy, namely skeletal muscle and adipose tissue when the body senses a lack of nutrition. Cachexia is characterized by increased pro\u2010inflammatory factors and adversely affects the patients’ ability to fight against infection and withstand treatment by chemotherapy and radiotherapy. It is often associated with an elevated basal metabolic rate, despite a decrease in physical activity and total energy expenditure. Muscle atrophy results from a decrease in protein synthesis, and increase in protein degradation, or a combination of both. This results in a decreased quality of life and reduced survival rates.<\/em><\/p>\n

Multiple abnormalities in protein, fat, and carbohydrate metabolism as well as peripheral hormone and neuropeptide metabolism have been reported as the cause of cancer cachexia. Investigations in humans suggest a central role of tumor\u2010induced inflammation as the primary cause of cachexia development.<\/em><\/p>\n

 <\/em> <\/strong><\/p>\n

Get FREE sample copy at: <\/strong><\/p>\n

https:\/\/www.delveinsight.com\/sample-request\/cancer-cachexia-CC-epidemiology-insights<\/a><\/strong><\/p>\n

 <\/p>\n

\"Cancer-Cachexia-Epidemiology\"<\/a><\/p>\n

The DelveInsight Cancer Cachexia epidemiology report gives a thorough understanding of the  Cancer Cachexia by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for  Cancer Cachexia in the US, Europe, and Japan.The report covers the detailed information of the  Cancer Cachexia epidemiology scenario in seven major countries (US, EU5, and Japan).<\/p>\n

 <\/p>\n

Key Highlights Of The Report<\/strong><\/p>\n

As per a Japanese study conducted by Aoyagi et al. “Cancer cachexia, mechanism and treatment”, cachexia occurs in the majority of terminal cancer patients and is responsible for the death of 22% of cancer patients.<\/em><\/p>\n

Several secondary studies suggest that the overall incidence of cachexia is high and in industrialized countries, such as, North America, Europe, Japan it is growing. It is currently estimated that cachexia affects approximately 9 million patients, which is about 1% of all patients with any disease.<\/em><\/p>\n

It is estimated that more than 30% of cancer  patients die due to cachexia, and more than  50% of patients die with cachexia being present.<\/em><\/p>\n

Among late stage patients, cachexia affects 50– 80% of cancer patients.<\/em><\/p>\n

 <\/p>\n

 Cancer Cachexia Epidemiology<\/strong><\/a><\/p>\n